Bristol Myers reports no new safety signals observed in five-year Sotyktu data

Bristol Myers (BMY) Squibb announced new five-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients with moderate-to-severe plaque psoriasis. The safety profile of Sotyktu remained consistent through five years with more than 5,000 patient-years of exposure in the trial, with no new safety signals identified. In patients who were treated continuously with Sotyktu , clinical response rates were maintained from Year 1 to Year 5, including Psoriasis Area and Severity Index 75, PASI 90 and static Physician’s Global Assessment 0/1. These data were presented at the Winter Clinical Dermatology Conference – Hawaii in Big Island, Waikoloa Village, HI taking place February 14-19. “These positive five-year results build upon the established profile of Sotyktu , a first-in-class TYK2 inhibitor, as a transformative oral treatment for psoriasis. As the leader in TYK2 innovation, we continue our relentless pursuit of bold science to elevate new standards of care for the patients we serve,” said Edgar Charles, MD, vice president and senior global program lead, Early & Late Development Immunology, Bristol Myers Squibb.